Appropriate Use Of Opioid Therapy For Patients With Pain
is no longer available for CME credit.

Accreditation

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and Integrity Continuing Education, Inc. PIM is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
PIM designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity

Nursing Continuing Education

Credit Designation
This education activity for 1.0 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurse's Credentialing Center's Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.

Program Overview
Opioids provide effective pain management for patients with acute and moderate to severe chronic pain who have not responded adequately to other therapies. However, prescription opioid abuse has escalated along with increased legitimate use in pain management. Because of potential prescription opioid abuse, patients and physicians may be reluctant to initiate opioid therapy for pain relief. Currently, there are clinical strategies to assist in prevention of opioid misuse, abuse, and diversion. The expert panel for this program will present and discuss these strategies and their implementation in clinical practice, risk assessment for aberrant drug-related behaviors, and management/monitoring strategies.

Learning Objectives
At the conclusion of this program, participants should be able to:

• Describe strategies to assess patients' risk for aberrant drug-related behaviors.
• Incorporate clinical practice strategies to limit abuse, misuse or diversion of opioids.
• Describe how to apply the Universal Precautions to the assessment and management of patients with chronic opioid therapy.

Target Audience

Physicians, nurse practitioners, physician assistants, and registered nurses involved in the care of patients with pain.

Faculty Disclosure Information

Disclosure of Conflicts of Interest
PIM assesses conflicts of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Charles E. Argoff, MD
Consultant: Eli Lilly and Company, Endo Pharmaceuticals Inc., King Pharmaceuticals, Inc., Nuvo Research Inc., PriCara, Shire, Vertex Pharmaceuticals
Research Grant: Endo Pharmaceuticals Inc., Pfizer Inc
Speakers Bureau: Eli Lilly and Company, Endo Pharmaceuticals Inc., King Pharmaceuticals, Inc., Pfizer Inc, PriCara

Perry G. Fine, MD
Consultant: Ameritox, Cephalon, Forest Labs, Johnson & Johnson (and affiliates), King Pharmaceuticals, Meda, Neuroadjuvants, Purdue Pharma
Speaker's Bureau: Grunenthal

Steven D. Passik, MD
Consultant: Cephalon, Eli Lilly and Company, King Pharmaceuticals, Inc., Ligand, Pricara,
Research Grant: Cephalon, Ligand
Speakers Bureau: Cephalon, Eli Lilly and Company, King Pharmaceuticals, Inc., Ligand, Pricara

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Gerald Johnson, III, PhD
Stock/shareholder: Amgen, MedCo Healthcare, Pfizer
Spouse is an employee of Bayer Healthcare AG
Linda Graham, RN, MSN
No real or apparent conflicts of interest to report
Jan Hixon, RN
No real or apparent conflicts of interest to report
Trace Hutchinson, PharmD
No real or apparent conflicts of interest to report

Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period December 19, 2009 through December 31, 2010, participants must:

• Register at www.DiscoveryHealthCME.com
• Read the learning objectives and faculty disclosures
• Study the educational activity
• Complete the posttest and evaluation form available at www.DiscoveryHealthCME.com
• A statement of credit will be issued only upon completion of the activity evaluation form and a completed posttest with a score of 70% or better

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, Integrity Continuing Education, Inc., and King Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Integrity Continuing Education, Inc., or King Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

For questions about the accreditation of this program, please contact PIM: info@pimed.com or visit www.pimed.com

Acknowledgement of Commercial Support
This program is funded by an educational grant from King Pharmaceuticals.